Home / GU oncology / Testis / Metastatic GCT

Testis → Metastatic germ-cell tumor

Last reviewed: 2026-09-22 · Next review: 2026-12-21

current — treatment is IGCCCG-directed and should be coordinated by an experienced germ-cell tumor team

Who this applies to

Population	Definition	Boundary
Metastatic seminoma or NSGCT	Use prechemotherapy AFP, hCG, LDH, primary site, and nonpulmonary visceral metastases for IGCCCG classification¹².	Do not use pre-orchiectomy markers alone¹⁵.
Good-risk NSGCT	Testis/retroperitoneal primary, no nonpulmonary visceral metastases, and AFP/hCG/LDH below IGCCCG intermediate thresholds¹.	Stage IIA/B marker-negative low-volume disease follows a separate RPLND/radiotherapy/chemotherapy decision pathway⁵.
Intermediate-/poor-risk NSGCT or intermediate-risk seminoma	Match exact IGCCCG group and organ burden¹².	No poor-prognosis IGCCCG seminoma category exists².

Standard options

Clinical context	Option	Key inclusion	Typical course
Good-risk seminoma or NSGCT	BEP ×3³	Cisplatin-based first-line treatment³⁵.	Three cycles³.
Good-risk disease with bleomycin contraindication	EP ×4⁵	Bleomycin cannot be used⁵.	Four cycles⁵.
Intermediate-risk seminoma or intermediate-/poor-risk NSGCT	BEP ×4¹⁵	IGCCCG risk group¹.	Four cycles⁵.
Bleomycin contraindication in intermediate-/poor-risk disease	VIP ×4 with primary G-CSF⁵	Expert-center management⁵.	Four cycles⁵.
Poor-risk NSGCT with unfavorable marker decline after cycle 1	Germ-cell center referral and consideration of marker-directed intensification⁴	GETUG-13 selected population⁴.	Protocol-driven⁴.

Therapy sequencing

IGCCCG setting or response branch	Treatment order	Evidence boundary
Good-risk seminoma or NSGCT	BEP ×3 → response assessment and residual-mass management³⁵.	The cited randomized BEP cycle trial is a good-prognosis population³.
Good-risk disease with bleomycin contraindication	EP ×4 → response assessment and residual-mass management⁵.	Do not substitute EP without explicitly documenting the bleomycin contraindication⁵.
Intermediate-risk seminoma or intermediate-/poor-risk NSGCT	BEP ×4 → response assessment and residual-mass management¹⁵.	No poor-prognosis seminoma group exists².
Bleomycin contraindication in intermediate-/poor-risk disease	VIP ×4 with primary G-CSF → response assessment⁵.	Use an expert germ-cell center; this is not simply an extra drug added to BEP⁵.
Poor-risk NSGCT with unfavorable marker decline after cycle 1	Refer to a germ-cell center for the GETUG-13-style marker-directed intensification discussion⁴.	The randomized signal applies only to the selected unfavorable-decline population; it does not establish universal first-line intensification⁴.

Surveillance and treatment de-escalation

Phase	Monitoring cadence	Stop, hold, or de-escalate	Re-escalation / next line
During BEP/EP/VIP⁵	Markers before each cycle; imaging after cycle 2–3 and at completion; audiometry and pulmonary function when bleomycin used⁵⁶.	Complete planned cycles (BEP ×3/×4, EP ×4, VIP ×4); hold bleomycin for pulmonary symptoms; dose-reduce cisplatin for renal toxicity per center policy. GETUG-13 intensification only for selected poor-risk unfavorable marker decline³⁴⁵.	Incomplete marker normalization or growing masses → salvage chemotherapy or post-chemo RPLND per germ-cell center⁵.
Post-chemotherapy remission (good/intermediate prognosis CR)⁵	See EAU-style schedule below⁵. Residual-mass PET for seminoma >3 cm; RPLND for NSGCT residual⁵⁶.	Stop chemotherapy at protocol completion; no maintenance in standard first-line⁵.	Relapse → salvage BEP/VIP/high-dose or experimental protocols at expert center⁵.

#### Post-remission follow-up after good/intermediate prognosis complete remission⁵

Modality	Year 1	Year 2	Year 3	Years 4–5
Markers ± visit⁵	4×	4×	2×	2×
Chest X-ray⁵	1–2×	1×	1×	1×
Abdominopelvic MRI/CT⁵	1–2×	At 24 mo	At 36 mo	At 60 mo
Thorax CT⁵	1–2× if lung mets at diagnosis	At 24 mo if indicated	—	At 60 mo if indicated

Poor-prognosis disease or incomplete remission needs individualized specialist follow-up rather than this minimal CR schedule⁵.
Residual mass management differs for seminoma (PET-directed observation or radiation) vs NSGCT (RPLND for teratoma/viable GCT)⁵.

Landmark evidence

Trial	Population	Intervention	Comparator	Primary endpoint	Clinically meaningful outcomes	Generalizability-critical differences
EORTC/MRC BEP trial	Good-prognosis GCT³	BEP ×3³	BEP ×4³	Progression-free survival³	Projected 2-year PFS 90.4% vs 89.4%³.	Good-prognosis population only³.
GETUG-13	Poor-prognosis GCT with unfavorable marker decline after cycle 1⁴	Dose-dense intensification⁴	Continued BEP⁴	Five-year PFS⁴	58.9% vs 46.7%; HR 0.65 (0.44–0.97). Five-year OS 70.9% vs 61.3%; HR 0.74 (0.46–1.20)⁴.	Selected marker-unfavorable poor-risk patients; OS was not statistically significant⁴.
IGCCCG Update Consortium	Contemporary metastatic NSGCT receiving first-line cisplatin/etoposide-based therapy¹	Prognostic cohort¹	No randomized comparator¹	Five-year PFS/OS prognosis¹	Good/intermediate/poor-risk NSGCT 5-year OS: 96%/89%/67%¹.	Prognostic cohort, not regimen-comparison evidence¹.

Biomarkers

Marker	Current clinic role	Emerging / investigational	How it changes decision now	Limits
AFP, hCG, LDH	IGCCCG classification and on-treatment response assessment¹²	—	Prechemotherapy values assign risk group and cycle count; serial markers guide response and post-remission surveillance¹²⁵.	Do not use pre-orchiectomy markers alone; pure seminoma should not produce AFP¹²⁵.
Early marker decline	Risk refinement in poor-risk NSGCT⁴	Broader real-time decline algorithms under study⁴	Unfavorable decline after cycle 1 in selected poor-risk patients triggers GETUG-13-style intensification discussion at a germ-cell center⁴.	Applies only to the selected unfavorable-decline population; not universal first-line intensification⁴.
FDG-PET	Selected seminoma residual-mass assessment after chemotherapy⁵	—	Helps triage observation vs further local therapy for seminoma residual >3 cm⁵.	Do not use for NSGCT residual disease; a single positive seminoma PET does not establish viable cancer⁵.
Histology (teratoma / viable GCT)	Directs post-chemotherapy residual-mass surgery for NSGCT⁵	—	Growing or residual NSGCT masses → RPLND for teratoma or viable GCT rather than PET-directed observation⁵.	Residual-mass histology is post-treatment pathology, not a pretreatment IGCCCG classifier⁵.

Upcoming research

Field direction: intensification of first-line BEP and randomized first-salvage high-dose versus conventional salvage remain the highest-impact ongoing experiments⁸⁹.

Trial	Why it may change care	Evidence status
P3BEP	Tests accelerated versus standard BEP ×4 in intermediate-/poor-risk metastatic GCT⁸.	Recruiting phase 3; no comparative efficacy result⁸.
TIGER	Compares first-salvage TIP with TI-CE high-dose chemotherapy/autologous transplant⁹.	Active, not recruiting; no efficacy result identified⁹.

Toxicity

Regimen and comparator	Trial-level safety outcomes	Selected named toxicities	Counseling focus
Dose-dense intensification versus continued BEP, GETUG-13	Toxic death 1% in each arm⁴.	Grade 3–4 neurotoxicity 7% vs 1%; grade 1–2 febrile neutropenia 17% vs 18%⁴.	Urgent contact for fever, infection, new/worsening neuropathy, dyspnea, dehydration, or severe vomiting⁴.
Standard BEP or VIP	No population-matched primary source with a complete named-event table was retrieved³⁵.	Do not assign unverified rates³⁵.	Counsel on cisplatin renal/hearing/neurologic effects, bleomycin pulmonary risk, myelosuppression, infertility, and survivorship risks⁵.

On-treatment monitoring

SOC/option regimen	Hallmark monitoring toxicity and available rate	Patient action / clinic response
BEP	A population-matched primary named-event table was not retrieved³⁵.	Check CBC, renal function, hearing, neuropathy, pulmonary symptoms, nausea/vomiting, and fertility plan; fever, dyspnea, new/worsening numbness, reduced urine output, or uncontrolled vomiting needs urgent contact⁵.
EP	A population-matched primary named-event table was not retrieved⁵.	Check CBC, renal function, hearing, neuropathy, nausea/vomiting, and fertility plan; fever, bleeding, new/worsening numbness, reduced urine output, or uncontrolled vomiting needs urgent contact⁵.
VIP with primary G-CSF	A population-matched primary named-event table was not retrieved⁵.	Check CBC, renal function, neurologic symptoms, hemorrhagic-cystitis symptoms, nausea/vomiting, and infection risk; fever, hematuria, confusion, reduced urine output, or uncontrolled vomiting needs urgent contact⁵.
GETUG-13 dose-dense intensification	Grade 3–4 neurotoxicity 7% vs 1%; grade 1–2 febrile neutropenia 17% vs 18%; toxic death 1% in each arm⁴.	Intensify CBC, neurologic, renal, hearing, pulmonary, and infection monitoring; fever, dyspnea, new/worsening neuropathy, bleeding, or severe vomiting needs urgent assessment⁴.

Epic phrase

#metastaticgct

Counseling: Good-prognosis BEP ×3 vs BEP ×4: projected 2-year PFS about 90% vs 89%. IGCCCG update: 5-year OS about 96%/89%/67% for good/intermediate/poor-risk NSGCT (prognostic cohort; no randomized comparator). GETUG-13 intensification for selected poor-risk unfavorable marker decline: 5-year PFS about 59% vs 47% with continued BEP (HR 0.65 vs continued BEP); 5-year OS 71% vs 61% with continued BEP (HR 0.74 vs continued BEP, CI crossed 1). Treatment at an experienced germ-cell center is essential.
Counseling: Reviewed surveillance and de-escalation: markers each cycle during BEP/EP/VIP; complete planned cycles then stop (no first-line maintenance). After good/intermediate-prognosis complete remission, EAU-style follow-up: markers about 4×/year years 1–2 then 2×/year years 3–5; chest X-ray 1–2× year 1 then yearly; abdominopelvic MRI/CT 1–2× year 1 then at 24, 36, and 60 months; thorax CT if lung mets at diagnosis as indicated. Poor-prognosis or incomplete remission needs individualized specialist follow-up. Residual-mass PET (seminoma) or RPLND (NSGCT) per guideline; relapse → salvage at an expert center.
Counseling: Reviewed sequence: use BEP ×3 for good-risk disease, EP ×4 when bleomycin is contraindicated, BEP ×4 for intermediate/poor-risk disease, VIP ×4 with primary G-CSF when bleomycin cannot be used, and consider marker-directed intensification only for the selected poor-risk unfavorable-decline population. ***
Monitoring: Check CBC, renal function, hearing, neuropathy, nausea/vomiting, and fertility plan with all cisplatin/etoposide regimens; monitor pulmonary symptoms with bleomycin, hemorrhagic-cystitis symptoms with ifosfamide, and infection risk with VIP/intensification. Contact oncology urgently for fever, new dyspnea, worsening neuropathy, dehydration, hematuria, confusion, or uncontrolled vomiting. ***
Decision: *** selects BEP / EP / VIP / high-volume germ-cell center referral / trial consideration.
Labs/NGS: AFP, hCG, LDH, CBC, CMP, renal function *; baseline audiology/pulmonary evaluation *.
Procedures: *** sperm banking, central access, post-chemotherapy residual-mass planning.
Follow-up: *** markers each cycle, toxicity, response imaging, and survivorship plan.

Edit markdown

Guideline references

Sources

Changelog

2026-09-22: Added EAU-style post-remission CR follow-up schedule for good/intermediate prognosis; expanded Biomarkers to five-column table including teratoma histology; mirrored post-chemo cadence in paired dotphrase.
2026-09-22: Renamed Upcoming trial results to Upcoming research; reframed for ongoing trials and field direction.
2026-09-22: Named comparator arms in paired dotphrase counseling for efficacy/toxicity rates.
2026-09-22: Added line-level source superscripts ([^n]) linked to numbered Sources.
2026-09-22: Added Surveillance and treatment de-escalation section; strengthened quantified benefit counseling in dotphrase.

2026-09-21: Added IGCCCG-directed treatment sequencing and all-regimen on-treatment monitoring for BEP, EP, VIP, and marker-directed intensification.
2026-09-21: Created metastatic GCT page with IGCCCG boundaries, first-line regimens, and source-qualified toxicity counseling.

Edit evidence markdown

Evidence page